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tive system
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The expression and role of STC-1 in the uterus during decidualisation and blastocyst implantation
The expression of STC-1 in maternal spiral arteries in pregnancy
The regulation of STC-1 secretion in the placenta during placental development
• Conclusions and future perspectives
BACKGROUND: Stanniocalcin-1 (STC-1) is a widely expressed glycoprotein hormone involved in a diverse spectrum of physiological and
pathophysiological processes including angiogenesis, mineral homeostasis, cell proliferation, inflammation and apoptosis. Over the last
20 years, numerous studies have reported STC-1 expression within female reproductive tissues including the uterus, ovaries and placenta
and implicated STC-1 in processes such as ovarian follicular development, blastocyst implantation, vascular remodelling in early pregnancy
and placental development. Notably, dysregulation of STC-1 within reproductive tissues has been linked to the onset of severe reproduc-
tive disorders including endometriosis, polycystic ovary syndrome, poor trophoblast invasion and placental perfusion in early pregnancy.
Furthermore, significant changes in tissue expression and in maternal systemic concentration take place throughout pregnancy and further
substantiate the vital role of this protein in reproductive health and disease.
OBJECTIVE AND RATIONALE: Our aim is to provide a comprehensive overview of the existing literature, to summarise the expres-
sion profile and roles of STC-1 within the female reproductive system and its associated pathologies. We highlight the gaps in the current
knowledge and suggest potential avenues for future research.
SEARCH METHODS: Relevant studies were identified through searching the PubMed database using the following search terms: ‘stan-
niocalcin-1’, ‘placenta’, ‘ovary’, ‘endometrium’, ‘pregnancy’, ‘reproduction’, ‘early gestation’. Only English language papers published
between 1995 and 2020 were included.
OUTCOMES: This review provides compelling evidence of the vital function that STC-1 plays within the female reproductive system. The
literature presented summarise the wide expression profile of STC-1 within female reproductive organs, as well as highlighting the putative
roles of STC-1 in various functions in the reproductive system. Moreover, the observed link between altered STC-1 expression and
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journals.permissions@oup.com
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the onset of various reproductive pathologies is presented, including those in pregnancy whose aetiology occurs in the first trimester. This
summary emphasises the requirement for further studies on the mechanisms underlying the regulation of STC-1 expression and function.
WIDER IMPLICATIONS: STC-1 is a pleiotropic hormone involved in the regulation of a number of important biological functions
needed to maintain female reproductive health. There is also growing evidence that dysregulation of STC-1 is implicated in common repro-
ductive and obstetric disorders. Greater understanding of the physiology and biochemistry of STC-1 within the field may therefore identify
possible targets for therapeutic intervention and/or diagnosis.
Key word: stanniocalcin-1 / STC1 / reproduction / placenta / ovary / endometrium / uterus / pregnancy / decidualisation /
implantation
Introduction
Stanniocalcin (STC) is a homodimeric glycoprotein first isolated in
bony fish (Wagner et al., 1986). It is secreted by the corpuscles of
Stannius, small endocrine glands located on the ventral surface of the
kidneys (Stannius, 1839). The function of these glands was elucidated
in 1964 when surgical removal resulted in hypercalcaemia (Fontaine,
1964). In the late 1980s, the anti-hypercalcaemic factor secreted by
the corpuscles of Stannius was purified and identified as STC (Wagner
et al., 1986; Lafeber et al., 1988). In the 1990s, a mammalian ortho-
logue was discovered following the successful cloning of mouse and
human cDNAs by two independent groups (Chang et al., 1995, 1996;
Olsen et al., 1996). The amino acid sequence of this orthologue shows
61% identity and 73% similarity with various fish STCs (Chang
et al., 1995). Moreover, 2 years after the discovery of mammalian
STC, several research groups identified a second member of the mam-
malian STC family (Chang and Reddel, 1998; DiMattia et al., 1998;
Ishibashi et al., 1998). This finding resulted in the renaming of mamma-
lian STC as STC-1 and the newly identified protein as STC-2 (Chang
and Reddel, 1998).
Structure of STC-1
Human STC-1 cDNA encodes a protein of 247 amino acids
(Chang et al., 1995). When compared to fish STC, the first 204
amino acids of human STC-1 show 92% similarity to that of
salmon, however, the last 43 residues at the C-terminus differ im-
mensely (Chang et al., 2003). In contrast, human STC-2 encodes a
protein of 302 amino acids which shows just 34% identity to both
human STC-1 and eel STC, with the greatest sequence similarity
present at the N-terminus (Chang et al., 2003). At this terminus,
a conserved cysteine motif is found in both fish and human STCs.
In STC-1, there are 11 cysteine residues with the same spacing as
those in fish STCs (Butkus et al., 1987; Wagner et al., 1992). STC-
2 possesses 15 cysteine residues, but only 10 of which have the
same spacing as fish STC and STC-1 (Moore et al., 1999). During
translation of the protein, 10 out of the 11 cysteines form intra-
chain disulphide linkages and the 11th cysteine residue functions
in forming the interchain dimer (Trindade et al., 2009), allowing
STC-1 to exist as a homodimer in its native state (Lafeber et al.,
1988). The lack of spatial conservation of the 11th cysteine
residue in STC-2 compared to fish STC/STC-1, combined with
the presence of four additional cysteine residues in this protein,
leads to the prediction that STC-2 has a different tertiary struc-
ture when compared with other STCs. Despite some structural
similarities between both STC-1 and STC-2, there is no evidence,
thus far, to suggest that these proteins are capable of heterodi-
merisation (Joshi, 2020). Another defining feature of STC-1,
which is also conserved amongst the STCs, is the presence of an
N-linked glycosylation consensus sequence (Asn-X-Thr/Ser).
In STC-1, this is present at residues 62–64; consistent with the
position of this sequence in fish STC (Butkus et al., 1987; Wagner
et al., 1992).
STC-1 appears to exist in several forms; the predicted molecular
weight of STC-1 is 27 kDa, however, studies have pointed to the exis-
tence of di- or multimers (Zhang et al., 1998; Paciga et al., 2002,
2005a). The dimeric 56 kDa form of STC-1 is known as STC50
(Paciga et al., 2005b). In addition, a number of higher molecular weight
STC-1 variants have been identified in ovarian cells, adrenocortical
cells and adipocytes, and are collectively referred to as ‘big STC’.
Within this category, at least three molecular weights: 84, 112 and
135 kDa have been described (Paciga et al., 2002, 2005a). STC-1 is se-
creted from most cells and contains a signal peptide sequence of 24
amino acids and a pro-sequence of 15 amino acids, both of which a
processed to yield the mature forms of the protein (Moore et al.,
1999). In most cell types, STC-1 is produced in large amounts intracel-
lularly in lightly glycosylated forms, however, when secreted, STC-1 is
highly glycosylated and phosphorylated by protein kinase C (Jellinek
et al., 2000).
STC-1 mammalian expression pattern and
pleiotropic roles
STC-1 has a wide expression pattern in mammals, with reported ex-
pression in many tissues including the heart, lungs, liver, adrenal gland,
kidney, ovary, prostate, colon, bone and spleen (Chang et al., 1995;
Olsen et al., 1996; Varghese et al., 1998; Yoshiko and Aubin, 2004;
Liu et al., 2010; Law et al., 2011). In humans, the STC-1 gene is
expressed predominantly as a 4 kb transcript and the highest expres-
sion levels are found in the ovary, kidney, prostate and thyroid
(Moore et al., 1999).
Consistent with its wide expression profile, STC-1 appears to
act in a pleiotropic manner in mammalian systems. It has been
implicated in a diverse range of processes including mineral ho-
meostasis (Olsen et al., 1996), angiogenesis (He et al., 2011; Law
and Wong, 2013), organogenesis (Jiang et al., 2000; Stasko and
Wagner, 2001), cell proliferation (Bai et al., 2017), apoptosis (Kim
et al., 2013), retinal degeneration (Roddy et al., 2012), cerebral is-
chaemia (Zhang et al., 2000), inflammation (Mohammadipoor
et al., 2016), tumourigenesis (Liu et al., 2010) and anti-oxidative
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activity (Kim et al., 2013; Wu et al., 2014; Bonfante et al., 2020).
In addition, numerous studies have highlighted the role of STC-1
in the physiology and pathophysiology of the female reproductive
system. These studies have outlined the wide expression of
STC-1 amongst female reproductive tissues including the uterus
(Stasko et al., 2001; Xiao et al., 2006; Allegra et al., 2009), pla-
centa (Uusküla et al., 2012; Juhanson et al., 2016; Abid et al.,
2020), and the developing maternal vasculature in early pregnancy
(Wallace et al., 2013). Amongst all female reproductive tissues,
the greatest expression is seen in the ovary (Varghese et al., 1998;
Deol et al., 2000). STC-1 expression is virtually undetectable in
the male testis (Varghese et al., 1998; Deol et al., 2000), indicating
that it has a specific role in female reproduction. This review will
provide an overview of the existing literature on the expression
and putative functions of STC-1 within female reproduction and
postulate future avenues of research (Table I).
Methods
This review was prepared by systematically searching the literature
using the PubMed database with the search terms: ‘stanniocalcin-1’,
‘placenta’, ‘ovary’, ‘endometrium’, ‘pregnancy’, ‘reproduction’, ‘early
gestation’. No restrictions were placed on the year published, but a
focus was placed on papers published between 1995 and 2020 and
only English language papers were included.
The expression pattern and
physiological and
pathophysiological roles of
STC-1 in the mammalian
female reproductive system
The expression pattern of STC-1 in the
ovary and its role in folliculogenesis
The expression pattern of STC-1 in the mammalian ovary
Early studies in mice revealed that the highest levels of STC-1 expres-
sion are found in the ovary where expression commences postnatally
and rises throughout development (Deol et al., 2000). Within the adult
mouse ovary, STC-1 gene and protein expression are detectable in
the secondary interstitial and theca interna cells, however, only STC-1
protein expression is found in oocytes and corpus luteal cells
(Varghese et al., 1998). The discordance between gene and protein
expression observed here could be indicative of a mechanism in which
oocytes and corpus luteal cells do not express the STC-1 gene but are
targets for STC-1 and therefore sequester the protein (Varghese et al.,
1998).
Although ovarian STC-1 gene expression remains constant through-
out the oestrous cycle in mice, STC-1 protein expression increases
during metoestrus I in the corpus luteum and declines thereafter
(Deol et al., 2000). During pregnancy and the post-partum period in
mice, ovarian STC-1 mRNA increases 15-fold, reaching a peak
between days 10–14 of gestation before dropping sharply at the time
of birth and rising again postpartum (Deol et al., 2000). Co-incident
with the rise in STC-1 gene expression, STC-1 protein levels also in-
crease, and the protein is detectable in the circulation for the first
time. Within the ovary, the spatial distribution of STC-1 mRNA
remains relatively constant, where it is detectable in the interstitium
and thecal compartment. In contrast, STC-1 protein localises to the
oocytes and thecal cells of primary and secondary follicles, as well as
to interstitial cells and corpora lutea (Deol et al., 2000). The active
regulation of ovarian STC-1 expression during gestation suggests a key
role for STC-1 in the physiology of this process. It is noteworthy that
STC-1 is the only secreted protein produced by the ovarian thecal in-
terstitial compartment that is significantly up-regulated during mouse
pregnancy (Deol et al., 2000).
Ovarian STC-1 expression has also been reported in pigs, rats and
bovines (Worthington et al., 1999; Paciga et al., 2002). Although not
fully characterised in rats and bovines, in pigs, STC-1 protein expres-
sion was reported in follicular fluid and was shown to be produced by
granulosa cells (Basini et al., 2010), while STC-1 gene expression was
detectable in the thecal layer of antral follicles, consistent with findings
in mice, rats and bovines (Varghese et al., 1998; Paciga et al., 2002).
During follicle development, STC-1 expression in thecal layer cells in
the swine ovaries begins to decrease, whilst STC-1 expression in gran-
ulosa cells increases (Basini et al., 2010). Granulosa cell STC-1 expres-
sion is also significantly increased under conditions of hypoxia and
anoxia (Basini et al., 2010). The increase in STC-1 expression in ovar-
ian follicles during follicular development observed here, combined
with its induction under conditions of oxygen deprivation are strongly
indicative of a role for STC-1 in ovarian follicle physiology, especially as
progressive hypoxia is established during follicle growth (Basini et al.,
2010).
Regulation of ovarian STC-1 expression
The mechanisms underlying the regulation of STC-1 expression in the
mammalian ovary are beginning to be appreciated. In a superovulation
mouse model, administration of human chorionic gonadotropin (hCG),
which mimics the effects of luteinising hormone (LH) and induces ovu-
lation, resulted in a 2.5-fold increase in steady-state STC-1 mRNA lev-
els, suggesting that STC-1 may be regulated by LH (Deol et al., 2000).
In rat and bovine thecal interstitial cells, hCG also stimulates STC-1 se-
cretion (Paciga et al., 2002). This response was mimicked by treatment
with forskolin, suggesting that STC-1 regulation is mediated through
the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)
pathway. The stimulatory effect of hCG on STC-1 expression was
only completely suppressed following inhibition of PKA, demonstrating
the requirement for PKA activation in hCG-induced STC-1 expression
in thecal interstitial cells (Paciga et al., 2002).
Structure and sub-cellular targeting of ovarian STC-1
The ovarian form of STC-1 is physically distinct and has been referred
to as ‘big STC’ (Paciga et al., 2002). In light of the discovery of STC-2
in 1998 (Chang and Reddel, 1998), big STC will hereafter be referred
to as big STC-1 for clarity. Cellular and secreted STC-1 from thecal in-
terstitial cells are substantially larger than STC50 which is found in
other mammalian tissues. In the native state, STC-1 derived from the-
cal interstitial cells comprises three molecular mass species of 84, 112
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Table I A summary of the expression pattern and roles of stanniocalcin-1 (STC-1) in different reproductive tissues across a
number of species.












Ovary Human Not reported Follicular fluid Not reported Regulation of IGF activity
through PAPP-A
inhibition
Jepsen et al. (2016)
Mouse Newborn ovary: Specific




Not reported Gestation and lactation Deol et al. (2000)
5 days old: Stromal cells
surrounding unilaminar and
multilaminar follicles




2 weeks old: Thecal and
interstitial cells, granulosa
cells









oocytes, thecal and interstitial
cells
During gestation: Thecal
and interstitial cells, luteal
cells
During gestation:
Primary and secondary follicle
oocytes, thecal cells, intersti-
tial cells, luteal cells
Post-partum: Thecal and
interstitial cells, luteal cells
Post-partum: Thecal and
interstitial cells, luteal cells,
primary, secondary and antral
follicle oocytes








Paciga et al. (2002)
Luo et al. (2004)





Basini et al. (2010)
Baioni et al. (2011)
Bovine Thecal interstitial cells, luteal
cells (only when isolated
from native environment)












Paciga et al. (2003)
Paciga et al. (2004)














Khatun et al. (2020)
Allegra et al. (2009)
Mouse Uterine epithelium, mesome-
trial stromal cells, mesome-
trial lateral sinusoids





Stasko et al. (2001)







Xiao et al. (2006)
Pig Luminal epithelium Uterine luminal fluids Not reported Blastocyst implantation Song et al. (2009)
Bovine Endometrium Luminal epithelium, glandular
epithelium, subepithelial
stroma, uterine luminal fluid
Not reported Not reported Mu~noz et al. (2017)
Continued
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and 135 kDa. Although still uncertain, it was postulated that the in-
creased mass may be due to post-translational modifications, including
glycosylation (Paciga et al., 2002). However, enzymatic treatment of
thecal interstitial cell-derived STC-1 to remove N-glycosylation had no
effect, indicating that the mass variation is not due to differential glyco-
sylation (Paciga et al., 2002). Chemical reduction of big STC-1 resulted
in a 45 kDa species, implying that the three molecular masses are poly-
mers of two or more subunits which are stabilised by disulphide link-
ages. It is hypothesised that the unique structure of ovarian STC-1
may explain its presence in the circulation during gestation and lacta-
tion due to differences in clearance kinetics between big STC-1 and
STC50 (Paciga et al., 2002).
Although STC-1 receptors in reproductive tissues have been little
studied, ovarian big STC-1 receptors have been described (Paciga
et al., 2003). Through the use of an STC-1 alkaline phosphatase fusion
protein, composed of mouse STC-1 cDNA fused to the human pla-
cental alkaline phosphatase gene (McCudden et al., 2002; Paciga et al.,
2003), high concentrations of STC-1 receptors have been identified in
cultured bovine luteal cells. Within these cells, significant populations
of receptors have been found in cholesterol/lipid storage droplets
(Paciga et al., 2003). Some targeting to the luteal cell plasma mem-
brane is also evident, but the affinity of the plasma membrane receptor
is 10-fold lower than that of the cholesterol/lipid storage droplets re-
ceptor (Paciga et al., 2003). This receptor-mediated targeting in luteal
cells provides an explanation for the observed discordances in the pat-
terns of STC-1 mRNA and protein distribution in ovarian cells. For ex-
ample, although both STC-1 gene and protein expression are
detectable in the thecal interstitial compartment in mice, rats and
bovines (Varghese et al., 1998; Deol et al., 2000; Paciga et al., 2002),
only STC-1 protein expression is present in oocytes and corpus luteal
cells (Varghese et al., 1998; Deol et al., 2000), thus, it is postulated
that oocytes and luteal cells may be targets for STC-1 in this case and
sequester the protein (Varghese et al., 1998).
The regulation of STC-1 expression in luteal cells and its function in
steroidogenesis
Although in vivo luteal cells do not express the STC-1 gene, when iso-
lated and maintained in culture, STC-1 gene expression can be
induced (Paciga et al., 2004). In this context, bovine luteal cells are ca-
pable of expressing and secreting big STC-1 similarly to thecal intersti-
tial cells (Paciga et al., 2004). Unlike in thecal interstitial cells, big STC-
1 production by luteal cells is not regulated by LH but is regulated by
prostaglandin E2. Similar to LH-induced STC-1 expression from thecal
interstitial cells, positive regulation of STC-1 expression in luteal cells is
mediated through the PKA pathway (Paciga et al., 2004).
Negative regulation of STC-1 expression in luteal cells is achieved
by sex steroids; both progesterone and oestradiol suppress STC-1 re-
lease from luteal cells and STC-1 expression and secretion are re-
duced to undetectable levels in the presence of androstenedione
(Paciga et al., 2004). Both progesterone and oestradiol are autocrine
regulators of luteal cell function in vivo (Okuda et al., 2001; Berisha
et al., 2002; Cassar et al., 2002; Van Den Broeck et al., 2002a,b), thus,
it is possible that these steroids act in concert in vivo to suppress luteal
cell STC-1 production (Paciga et al., 2004). Moreover, in vivo luteal
cells are in close proximity to the source of androgens, such as andro-
stenedione, which may further explain the observed absence of STC-1
in luteal cells in the intact ovary (Paciga et al., 2004). Though it will re-
quire further study to fully understand the regulation of luteal cell
STC-1 expression in vivo, it is feasible that STC-1 production in this
context is only suppressed under conditions of high sex steroid pro-
duction, however, when these levels are reduced, for example in the
luteal phase of the oestrous cycle or after parturition (Kanchev and
Dobson, 1976; Mostl et al., 1981), luteal cell STC-1 production could
take place in vivo (Paciga et al., 2004).
Although the regulation of STC-1 expression in luteal cells in vivo is
not fully understood, it is apparent that thecal interstitial cell-derived
STC-1 may be sequestered by luteal cells in vivo as they contain high lev-
els of the STC-1 protein (Varghese et al., 1998). It appears that this
relates to a role in progesterone synthesis. Basal and hCG-stimulated
progesterone secretion from luteal cells is significantly decreased by big
STC-1 (Paciga et al., 2003). Consistent with the requirement for PKA ac-
tivation in hCG-induced expression of STC-1 in thecal interstitial cells
(Paciga et al., 2002), big STC-1 receptors in luteal cells are up-regulated
in response to PKA activation (Paciga et al., 2003). Thus, it is conceivable
that in vivo big STC-1 may be targeted to luteal cells for the purpose of
decreasing PKA-activated steroidogenesis (Paciga et al., 2003) (Fig. 1).
..................................................................................................................................................................................................................................
Table I Continued
















Not reported Blastocyst implantation Song et al. (2006)
Horse Endometrial glands Uterine luminal fluids Not reported Conceptus attachment
and development
Kikuchi et al. (2011)
Vasculature Human Endothelial cells, vascular
smooth muscle cells
Not reported Not reported Spiral artery remodelling Wallace et al. (2013)









Placental development Uusküla et al. (2012)
Juhanson et al. (2016)
Abid et al. (2020)
Note: Postulated roles are in grey text.
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.The role of STC-1 in granulosa cells and in folliculogenesis
In addition to its role in modulating steroidogenesis in luteal cells, the-
cal interstitial cell-derived STC-1 has also been implicated in ovarian
follicular development (Luo et al., 2004). Similar to the observed
effects in bovine luteal cells, STC-1 causes a decrease in gonadotropin-
induced progesterone production in granulosa cells (Luo et al., 2004).
Treatment of rat granulosa cells with recombinant N-glycosylated
STC-1 resulted in suppression of FSH-induced progesterone biosyn-
thesis and LH receptor expression but, had little effect on oestradiol
production (Luo et al., 2004) (Fig. 1). Specific inhibition of progester-
one biosynthesis without effect on oestrogen production in this way
has also been observed in other ovarian paracrine factors which are
postulated as luteinisation inhibitors (Falck, 1959; Smith et al., 1975). It
is, therefore, possible that STC-1 acts as a luteinisation inhibitor within
ovarian follicles, but this will require further investigation. Treatment of
rat granulosa cells with STC-1 also results in a decrease in expression
of CYP11A mRNA, a rate-limiting enzyme in progesterone biosynthe-
sis (Zlotkin et al., 1986; Goldring et al., 1987; Oonk et al., 1990), and
this is the possible mechanism through which STC-1 mediates an effect
on progesterone production in granulosa cells (Luo et al., 2004). To
induce these cell-specific effects, STC-1 likely binds to several high spe-
cificity and affinity receptors located on the plasma membrane of gran-
ulosa cells, and when inside the cell, STC-1 acts downstream of
adenylyl cyclase in the cAMP/PKA pathway to exert its effects on pro-
gesterone biosynthesis and LH receptor induction (Luo et al., 2004).
These findings are indicative of a follicular paracrine system in which
thecal interstitial-derived STC-1 acts to dampen gonadotropin-induced
granulosa cell differentiation (Luo et al., 2004). For STC-1 to act in this
inhibitory manner in vivo, it is clear that stringent regulation of its ex-
pression must occur to permit granulosa cell differentiation. It was
demonstrated that gonadotropin treatment of thecal interstitial cells
suppresses STC-1 expression, suggesting a mechanism in which prior
suppression of thecal interstitial STC-1 by gonadotropins is required to
allow gonadotropin-induced granulosa cell differentiation (Luo et al.,
2004). However, previous studies also report stimulation of STC-1 ex-
pression in thecal interstitial cells following gonadotropin treatment
(Deol et al., 2000; Paciga et al., 2002), contrary to the gonadotropin-
induced suppression of STC-1 from thecal interstitial cells reported by
Luo et al. (2004). It is possible that differences in methodology could
contribute to this discrepancy, therefore, further research is required
to understand the regulation of STC-1 expression in thecal interstitial
cells.
As well as modulating granulosa cell differentiation during ovarian
follicular development, STC-1 has also been implicated in the regula-
tion of granulosa cell redox status (Baioni et al., 2011). It is thought
that the balance of pro-oxidant/anti-oxidant factors within the ovarian
follicle plays an important role in folliculogenesis (Basini et al., 2008)
and that some reactive oxygen species (ROS) induce the expression of
genes involved in oocyte maturation and follicular development
(Behrman et al., 2001; Agarwal et al., 2005). In granulosa cells, STC-1
Figure 1. A schematic illustration of the proposed regulation and roles of thecal cell-derived STC-1 in granulosa cells and luteal
cells in the developing follicle. Demonstrated roles are shown with solid arrows, postulated roles are shown with dashed arrows. cAMP, cyclic
adenosine monophosphate; IGF, insulin-like growth factor; PKA, protein kinase A; ROS, reactive oxygen species; STC-1, stanniocalcin-1.
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stimulates the production of superoxide anion (Baioni et al., 2011), a
ROS implicated in modulating ovarian steroidogenesis (Sawada and
Carlson, 1996; Jain et al., 2000; Behrman et al., 2001) and in inducing
ovulation (Behrman et al., 2001; Fujii et al., 2005). The process
through which STC-1 stimulates superoxide anion production is
unclear; however, as STC-1 is known to have stimulatory effects on
the mitochondrial electron transport chain (Ellard et al., 2007), and the
mitochondria are the main sites of superoxide anion generation
(Murphy, 2009), it is possible that the action of STC-1 on mitochon-
dria could explain this effect (Baioni et al., 2011). Although STC-1
does not affect the activity of superoxide dismutase, which catalyses
the dismutation of superoxide anion to hydrogen peroxide, it has been
shown to influence both catalase and peroxidase which scavenge hy-
drogen peroxide (Baioni et al., 2011). High concentrations of STC-1
stimulate catalase activity, thereby reducing levels of hydrogen perox-
ide. Conversely, elevated levels of STC-1 result in a decrease in perox-
idase activity, potentially caused by the catalase-mediated reduction in
its substrate, hydrogen peroxide (Baioni et al., 2011). These findings
suggest that STC-1 may play an important role in ROS homeostasis in
granulosa cells during folliculogenesis which may be essential to regu-
late their activity (Baioni et al., 2011) (Fig. 1), but the specific mecha-
nisms underlying these processes, as well as their direct effect on
granulosa cell function remain to be elucidated.
Regulation of pregnancy-associated plasma protein-A (PAPP-A) by
STC-1/2 in ovarian follicles
The insulin-like growth factor (IGF) system is involved in several physi-
ological ovarian functions including follicular growth, steroidogenesis
and ovulation (Kwintkiewicz and Giudice, 2009). IGF signalling is regu-
lated by the actions of the metzincin metalloproteinase, pregnancy-
associated plasma protein-A (PAPP-A) (Oxvig, 2015) which is known
to be secreted from granulosa cells (Conover et al., 2001). PAPP-A
cleaves a subset of IGF binding proteins, counteracting their inhibitory
effects and causing release of bioactive IGF (Oxvig, 2015). In vitro,
STC-1 inhibits PAPP-A proteolytic activity through non-covalent, high
affinity binding (Kløverpris et al., 2015). More recently, it has been
established that these protein interactions also take place in vivo within
human ovaries (Jepsen et al., 2016).
Coincident expression of both PAPP-A and STC-1 is evident
throughout follicular development; PAPP-A and STC-1 are localised
together in the primordial, late primary and antral follicles (Jepsen
et al., 2016). Following follicle stimulation with hCG, the correlation
between the intrafollicular concentration of PAPP-A and its activity is
altered. hCG stimulation results in an increase in the intrafollicular con-
centration of PAPP-A, whilst a decrease in its activity is observed
(Jepsen et al., 2016). Inhibitory complexes between PAPP-A and STC-
1 are detectable in follicular fluid at this stage, explaining the decline in
PAPP-A activity, despite an increase in its concentration (Jepsen et al.,
2016). STC-2 is also expressed concurrently with STC-1 and PAPP-A
and is found to form covalent inhibitory complexes with PAPP-A in fol-
licular fluid (Jepsen et al., 2016). The finding of native complexes be-
tween PAPP-A and STC-1/2 in follicular fluid is strongly indicative of a
model in which STC-1/2 inhibit the actions of PAPP-A, thus resulting
in a decrease in bioactive IGF release (Jepsen et al., 2016). IGF activity
in the mammalian ovaries has been linked to follicular growth via stim-
ulation of the mitotic activity of granulosa cells (Kadakia et al., 2001;
Spicer and Aad, 2007). At the midcycle peak, however, granulosa cell
proliferation ceases, consistent with the decrease in PAPP-A activity in
the follicular fluid (Jepsen et al., 2016). Thus, it is conceivable that
STC-1/2 may be involved in the decline in granulosa cell proliferation
during this stage of folliculogenesis through their actions in inhibiting
PAPP-A (Jepsen et al., 2016) (Fig. 1). It remains to be determined
whether STC-1/2-mediated inhibition of PAPP-A occurs in tissues
other than the ovary.
The expression and postulated roles of
STC-1 in the human endometrium and
dysregulation in reproductive pathologies
The human endometrium is a dynamic tissue which undergoes a num-
ber of important histological and structural changes throughout the
menstrual cycle in preparation for embryo implantation and subse-
quent shedding and regeneration in non-conception cycles (Talbi et al.,
2006). Endometrial STC-1 expression has been described in several
mammals, including rats, pigs, sheep and horses (Song et al., 2006,
2009; Xiao et al., 2006; Kikuchi et al., 2011). STC-1 expression in the
human endometrium has been more recently described (Aghajanova
et al., 2016; Khatun et al., 2020).
Several high-throughput gene expression profiling studies have impli-
cated STC-1 in human endometrial functions and report fluctuating tis-
sue expression levels throughout the menstrual cycle. Endometrial
expression of STC-1 is high during the mid-secretory phase (MSE)
(Talbi et al., 2006; Aghajanova et al., 2016; Boggavarapu et al., 2016;
Suhorutshenko et al., 2018), correlating with the expression of recep-
tivity markers during the window of implantation (Allegra et al., 2009).
Aberrant endometrial expression of STC-1 has also been implicated in
hypoxia-mediated abnormal uterine bleeding of long-acting progestin-
only contraceptive users (Shapiro et al., 2015). The specific expression
pattern and cellular localisation of STC-1 in the human endometrium
in both normal and diseased states have been poorly studied and the
existing literature suffers from restricted sample sizes. The findings,
however, may still be clinically relevant but highlight the need for fur-
ther research in this area.
Dysregulation of STC-1 in endometriosis
Endometriosis is an oestrogen-dependent gynaecological condition
characterised by chronic inflammation and the presence and growth of
ectopic endometrial tissue (Hickey et al., 2014). It affects between
10% and 15% of reproductive aged women and is often associated
with severe and chronic pain and infertility (Mehedintu et al., 2014).
Despite its prevalence, the aetiology of endometriosis is poorly under-
stood. Altered endometrial expression of STC-1 in endometriosis has
been described (Aghajanova et al., 2016).
In healthy women, endometrial STC-1 gene expression fluctuates
throughout the menstrual cycle (Aghajanova et al., 2016). In the endo-
metrium of women with endometriosis, however, STC-1 gene expres-
sion is significantly increased in MSE compared to the proliferative
phase (PE) or early secretory phase (ESE). Interestingly, endometrial
STC-1 gene expression in PE and MSE is 2-fold higher in women with
endometriosis compared to healthy women (Aghajanova et al., 2016).
Although not reported for women with endometriosis, up-regulation
of STC-1 protein in endometrial fluid in MSE compared to ESE is ob-
served in healthy women (Aghajanova et al., 2016). Abundance of
STC-1 in the secretome of receptive MSE endometrium is highly
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indicative of a role in the process of implantation (Aghajanova et al.,
2016), but further studies are required to confirm this role in the hu-
man endometrium.
In terms of cellular localisation in the MSE human endometrium,
STC-1 protein is expressed in the cytoplasm of epithelial and stromal
cells from both women with and without endometriosis (Aghajanova
et al., 2016). In the endometrium of healthy women, STC-1 protein
expression appears higher in the luminal epithelium and stroma com-
pared to the glandular epithelium. In the endometrium of women with
endometriosis, no difference in STC-1 protein expression was detect-
able between epithelial cells, however, endometrial stromal cell (eSC)
expression of STC-1 was reduced in endometriosis compared to
healthy cells (Aghajanova et al., 2016).
In endometrial stromal fibroblasts decidualised in vitro with cAMP,
STC-1 gene expression was dramatically up-regulated over 230-fold in
healthy women, however, in women with endometriosis, only a 45-
fold increase is observed (Aghajanova et al., 2016). Of note, STC-1
gene expression is not significantly affected in endometrial stromal
fibroblasts decidualised with oestradiol and progesterone in either the
healthy or endometriosis group, suggesting that endometrial STC-1 ex-
pression is not regulated by sex steroids (Aghajanova et al., 2016),
consistent with findings in the equine endometrium (Kikuchi et al.,
2011). It does appear evident, however, that STC-1 expression in en-
dometrial stromal fibroblasts is induced by cAMP and therefore may
be mediated though the PKA pathway, but confirmation of this will re-
quire further investigation. The observed reduction in the up-regulation
of STC-1 in cAMP-decidualised endometrial stromal fibroblasts from
women with endometriosis may be indicative of a role in the patho-
genesis of decidualisation defects (Aghajanova et al., 2016).
Dysregulation of STC-1 in polycystic ovary syndrome
In addition to endometriosis, STC-1 has also been implicated in the
pathology of polycystic ovary syndrome (PCOS) (Khatun et al., 2020).
PCOS is a common endocrine disorder which affects 8–12% of
women of reproductive age. It is characterised by oligo-anovulation,
hyperandrogenism and dysregulated metabolism (Teede et al., 2018).
Moreover, women with PCOS present with subfertility and are at in-
creased risk of developing pregnancy complications as well as endome-
trial cancer (Piltonen et al., 2013; Katulski et al., 2015; Palomba et al.,
2015; El Hayek et al., 2016; McDonnell and Hart, 2017). Given the en-
dometrial expression of STC-1, and its link to modulation of hypoxic
and inflammatory responses essential for normal endometrial physiol-
ogy (Westberg et al., 2007a,b; Mohammadipoor et al., 2016), it is pos-
tulated that STC-1 may play a role in the pathogenesis of PCOS.
Data obtained from the investigation of endometrial biopsy samples
has revealed increased endometrial expression of STC-1 mRNA in
MSE and late secretory phase (LSE) in both healthy women and those
with PCOS (Khatun et al., 2020). In younger women with a more se-
vere PCOS phenotype and higher BMI, STC-1 gene expression did
not increase in the secretory phase as it did in the other groups. STC-
1 protein expression increased from PE to LSE in stromal cells, but
only in healthy women and not in those with PCOS, which is poten-
tially indicative of a stromal cell defect in women with PCOS (Khatun
et al., 2020). Further investigation of eSCs challenged with cAMP, pre-
viously established as an inducer of STC-1 expression, has revealed
that eSCs from healthy women displayed a strong increase in STC-1
expression (Khatun et al., 2020). eSCs from women with PCOS
showed a significantly smaller increase in expression of STC-1 in re-
sponse to cAMP compared to that in eSCs from healthy controls.
Furthermore, reduced basal PKA activity was demonstrated in eSCs
from women with PCOS, suggesting a defect in cAMP-mediated PKA
signalling in PCOS stromal cells (Khatun et al., 2020). In healthy
women, STC-1 expression from eSCs was also stimulated under hyp-
oxic conditions (Khatun et al., 2020). In contrast, STC-1 expression in
eSCs from women with PCOS was not triggered by hypoxia and its
secretion from eSCs was also reduced in these conditions (Khatun
et al., 2020). As hypoxia is a crucial factor in embryo implantation
(Daikoku et al., 2003; Matsumoto et al., 2018), it is possible that the
observed impairment in STC-1 expression under these conditions
could contribute to the subfertility associated with PCOS.
The role of obesity in influencing endometrial STC-1 expression has
also been established. Increased secretory phase endometrial STC-1
expression is present in overweight/obese women compared to
women with a lower BMI, however, these BMI-specific differences are
not apparent in women with PCOS (Khatun et al., 2020). Elevated
STC-1 expression in the secretory phase endometrium in overweight/
obese women suggests that obesity may be a stress factor which leads
to the induction of endometrial STC-1 expression, however, this
mechanism appears absent in women with PCOS (Khatun et al.,
2020). A 3-month lifestyle intervention, commonly recommended as
the first-line therapy for women with PCOS and obesity (Teede et al.,
2018), was unable to restore STC-1 expression in the PCOS endome-
trium, corroborating the report of impaired STC-1 regulation in the
PCOS endometrium, regardless of BMI (Khatun et al., 2020).
The expression and role of
STC-1 in early gestation
The expression and role of STC-1 in the
uterus during decidualisation and blastocyst
implantation
Blastocyst implantation is a tightly controlled physiological process
which requires complex interactions between the developing embryo
and the uterus (Paria et al., 2002). Dramatic changes in gene expres-
sion accompany this process to aid decidualisation and remodelling of
the uterine architecture (Stasko et al., 2001). Several studies have im-
plicated STC-1 in this process in numerous species through the obser-
vation of dynamic changes in its gene and protein expression
throughout both the decidualisation and implantation processes. The
strategies underlying these processes vary significantly across species,
thus STC-1 expression and localisation also appear to be species-
specific. Herein, the uterine expression patterns and putative roles for
STC-1 in decidualisation and implantation in several mammalian spe-
cies are described.
Early studies in mice first suggested a role for STC-1 in decidualisa-
tion and blastocyst implantation (Stasko et al., 2001). Following blasto-
cyst implantation, STC-1 gene expression in the mouse uterus shifts
from the uterine epithelium to the mesometrial stromal cells. Between
days 6.5–8.5 of pregnancy, STC-1 gene expression then moves to cells
of the mesometrial lateral sinusoids and declines thereafter (Stasko
et al., 2001). The localisation of STC-1 protein varies from its gene
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expression. STC-1 protein is reported to accumulate in epithelial, stro-
mal and decidual cells, as well as in fetal giant trophoblast cells
throughout the implantation process. In addition, it localises to decidu-
alising anti-mesometrial cells (Stasko et al., 2001). The mRNA-protein
disparities observed here indicate that STC-1 is transcribed in one cell
type and then sequestered by target cells for action, suggestive of a
paracrine/autocrine signalling role during these processes in the uterus
(Stasko et al., 2001).
The pattern of STC-1 expression during implantation has been fur-
ther investigated in rats (Xiao et al., 2006). Here, similar expression
patterns to those seen in mice have been reported. In rats, STC-1
mRNA is present in the stromal cells surrounding the implanting blas-
tocyst. It is notable, however, that in pseudopregnant rats, corre-
sponding STC-1 gene expression is not observed suggesting that STC-
1 expression in the uterus is specifically induced by developing em-
bryos and implanting blastocysts. This hypothesis is further evidenced
by the observation that STC-1 mRNA is maintained at a basal level
during an induced delay in implantation but is elevated following termi-
nation of the delay. In addition, STC-1 gene and protein expression
are concentrated at sites with the implanting blastocyst compared to
other uterine segments (Xiao et al., 2006).
In contrast to rodents, studies in sheep have revealed that STC-1
gene expression is confined to endometrial glandular epithelial cells
and is induced by progesterone (Song et al., 2006). Expression is de-
tectable in the endometrial glands from day 16, consistent with the
start of blastocyst implantation (Spencer et al., 2004), to day 120 of
gestation and is stimulated by the placental hormones, ovine placental
lactogen and ovine growth hormone (Song et al., 2006). STC-1 protein
is also present in the endometrial glands, and is secreted into the uter-
ine lumen where it is detectable in uterine secretions, allantoic fluid
and placental areolae which transport uterine gland secretions across
the placenta and into the fetal-placental circulation. Secretion of STC-1
from uterine glands into the fetal circulation and allantoic fluid in this
manner may suggest an exocrine role in this system (Song et al.,
2006).
In pigs, STC-1 mRNA is present exclusively in the luminal epithelium
at the uterine-conceptus interface during the period of conceptus at-
tachment prior to implantation, between days 12–25 of pregnancy
(Song et al., 2009). Consistent with observations in sheep, STC-1 ex-
pression is also induced by progesterone and is initially stimulated by
oestrogen in the luminal epithelium at implantation sites. Expression is
later inhibited, however, by the combined effects of oestrogen and
progesterone. STC-1 protein is also detectable but is found in uterine
luminal fluids (Song et al., 2009). Although a specific role has yet to be
elucidated, it is postulated that in pigs, STC-1 may be involved in im-
plantation through effects on uterine receptivity and remodelling of the
trophoectoderm for conceptus elongation (Song et al., 2009).
STC-1 expression in the equine uterus is remarkably similar to that
seen in the pig uterus, where increased endometrial STC-1 expression
coincides with conceptus attachment (Kikuchi et al., 2011). STC-1 pro-
tein is detectable in uterine luminal fluids, indicating secretion of STC-1
from the endometrial glands towards the conceptus (Kikuchi et al.,
2011), which is consistent with observations in pigs and sheep (Song
et al., 2006, 2009). In the equine uterus, it is also suggested that STC-
1 expression is regulated by conceptus oestrogen (Kikuchi et al.,
2011). As the STC-1 gene lacks any steroid receptor binding sites in
its upstream region, it is likely that the effect of steroid hormones on
STC-1 expression is indirect (Kikuchi et al., 2011). STC-1 possesses
early growth response factor (Egr) binding sites in its upstream region
and, since ligand-activated oestrogen receptors can up-regulate gene
transcription indirectly through transcription factors such as the Egr
family, it is possible that this represents an indirect mechanism for ste-
roid hormone action on STC-1 expression (Almeida et al., 2006;
Melamed et al., 2006). In addition, other factors present in the equine
uterus, such as vascular endothelial growth factor A or hypoxia-
inducible factor 1a, can be activated by oestrogen in vitro (Kazi and
Koos, 2007; Bake et al., 2008) and are reported to induce expression
of STC-1, possibly indicating another indirect mechanism (Wary et al.,
2003; Yeung et al., 2005).
It is interesting that the uterine expression of STC-1 during early
pregnancy appears to differ amongst species. STC-1 expression in pigs,
horses and rodents is detectable earlier than in sheep, from the point
of conceptus attachment (Stasko et al., 2001; Song et al., 2006, 2009;
Xiao et al., 2006; Kikuchi et al., 2011). In pigs, STC-1 expression
appears to be limited only to the peri-implantation period of preg-
nancy, unlike rodents and sheep where expression continues into the
later stages of placentation (Stasko et al., 2001; Song et al., 2006,
2009; Xiao et al., 2006). The observed temporal and spatial expres-
sion of STC-1 in pigs and horses suggests that STC-1 may play an im-
portant role in conceptus attachment during implantation (Song et al.,
2009; Kikuchi et al., 2011), whereas in rodents and sheep, STC-1 may
be involved in later stages of implantation and decidualisation. It is in-
triguing that in bovines, endometrial STC-1 expression does not ap-
pear to be pregnancy-specific as comparable expression is detected in
the non-pregnant, cyclic uterus (Mu~noz et al., 2017). It is likely that
these inter-species differences manifest from intrinsic differences in pla-
cental structure and development between species.
Despite our knowledge of the role of STC-1 in blastocyst implanta-
tion in non-human mammals, its corresponding role in humans has
been little studied due to the challenges in investigating human preg-
nancy in vivo. A 2009 study by Allegra and colleagues is, thus far, the
only study to implicate STC-1 in the process of blastocyst implantation
in humans. By investigating endometrial gene expression in women
undergoing IVF treatment who subsequently became pregnant it was
found that STC-1 is one of only six genes which retains homogenous
expression during the window of implantation (Allegra et al., 2009).
Confirmation of STC-1 involvement in implantation will, however,
require further study.
From the numerous studies discussed herein, it appears evident that
STC-1 plays a role in the uterus during early pregnancy, particularly dur-
ing the implantation/peri-implantation period. Therefore, data obtained
from studies using genetically engineered mouse models are surprising.
In STC-1 null mice, no important change in fertility was detectable
(Chang et al., 2005). It is possible that there may be other gene prod-
ucts capable of fully compensating for STC-1 in this context. The poten-
tial for STC-2 to act in this way was investigated in the same study,
however, no change in the expression of STC-2 in organs in the STC-1
null mice was detected, suggesting that this is not the compensatory
factor (Chang et al., 2005). In contrast, transgenic overexpression of
human STC-1 in mice results in reduced female reproductive capacity
(Varghese et al., 2002). It is unclear what causes this, but from the data
on uterine STC-1 expression in mice (Stasko et al., 2001), it is apparent
that dramatic and precise shifts in expression accompany blastocyst
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implantation, thus, it is postulated that transgenic overexpression may
interfere with this tightly controlled process (Varghese et al., 2002).
The expression of STC-1 in maternal spiral
arteries in pregnancy
In addition to its dynamic regulation and putative essential function in
establishing a healthy pregnancy, STC-1 has also been implicated in the
remodelling of the maternal vasculature which occurs early in pregnancy
(Wallace et al., 2013). During the second half of the menstrual cycle,
under the influence of progesterone, highly coiled arteries begin to form
at the myometrial-endometrial boundary of the uterus; these are known
as spiral arteries (Ferenczy et al., 1979). These arteries supply blood to
the endometrial layer and, during pregnancy, they span the inner myo-
metrium and decidua. During early pregnancy, spiral arteries undergo a
unique remodelling process in which they change from small, high resis-
tance vessels to large, low resistance vessels (Burton et al., 2009). This
remodelling results in large diameter vessels which are unresponsive to
vasoconstrictors allowing an unimpeded increase in blood flow to the
developing foetus (Osol and Mandala, 2009). During the remodelling
process, vascular smooth muscle cells (VSMCs) and endothelial cells
(ECs) are lost from the spiral arteries and are replaced by fetal tropho-
blast cells (Pijnenborg et al., 1983; Burton et al., 1999). Trophoblast cells
disrupt the interactions of the VSMCs and ECs through processes
including apoptosis and dedifferentiation and supplant the vascular cells
(Whitley and Cartwright, 2009). The spiral artery remodelling process is
completed by 20–22 weeks of gestation (Sato et al., 2012).
Defects in maternal vasculature remodelling have been associated
with the onset of several pregnancy complications, including
pre-eclampsia, fetal growth restriction and pre-term labour. Although
these complications do not manifest until later in pregnancy, it is
thought that their pathology is established during the early stages of
pregnancy (Cartwright and Whitley, 2017). For example, spiral arteries
derived from pre-eclamptic pregnancies have a reduced mean external
diameter compared to those from normal pregnancies (200mm com-
pared to 500mm) (Brosens et al., 1972). This defect in vascular
remodelling dramatically reduces blood supply to the placenta resulting
in poor placental perfusion (Zhou et al., 1993; Redman and Sargent,
2001). Despite our knowledge of insufficient vascular remodelling in
early pregnancy, the specific mechanisms underlying the physiology and
pathophysiology of the process are poorly understood. A potential
role for STC-1 in this process, however, has been suggested.
STC-1 was first implicated in the process of spiral artery remodelling
following investigation of the role of fetal trophoblast secreted factors
on vascular cell gene expression (Wallace et al., 2013). The use of a
three-dimensional spheroid co-culture of ECs and VSMCs to represent
an inverted vessel lumen, revealed two-fold up-regulation of STC-1 fol-
lowing incubation with conditioned media from an extravillous tropho-
blast cell line (Wallace et al., 2013). The mechanisms underlying the
up-regulation of STC-1 within this system are not yet understood,
however, it is known that fetal trophoblast cells secrete a range of
growth factors and cytokines, including hepatocyte growth factor, vas-
cular endothelial growth factor, interleukin-1b, interleukin-6, platelet-
derived growth factor and placental growth factor (Wallace et al.,
2013). It is likely that a number of these factors will act either individu-
ally or in synchrony to stimulate STC-1 gene expression from vascular
cells and this will require further investigation.
Despite clear up-regulation of STC-1 in the remodelling vessel, its
specific function has yet to be described. It is evident from the current
research that a number of tightly controlled cellular events take place
during the vascular remodelling process (Whitley and Cartwright,
2010). The existing literature on the functional roles of STC-1 may
suggest its potential mechanisms of action within the remodelling spiral
artery. For example, STC-1 has been shown to inhibit the action of in-
flammatory cytokines, including tumour necrosis factor a (Chen et al.,
2008; Sheikh-Hamad, 2010), an important factor in the regulation of
vascular cell apoptosis in artery remodelling (Rastogi et al., 2012). In
addition, STC-1 antagonises the activity of vascular reactive factors, in-
cluding angiotensin II and hepatocyte growth factor (Zlot et al., 2003;
Liu et al., 2012; Moreau et al., 2012). Both factors are known to be
present within the environment of the remodelling spiral artery and
could influence the behaviour of vascular cells. Furthermore, overex-
pression of STC-1 has been shown to promote angiogenesis in vivo
and in vitro (Bell et al., 2001; Gerritsen et al., 2002; Liu et al., 2003; He
et al., 2011), suggesting that it may have different roles depending on
concentration or the local environment. It is crucial to maintain a bal-
ance of signals within the remodelling spiral artery to allow vessel
change but also apply limits. Therefore, it is possible that altering levels
of STC-1 acts as a local control mechanism to prevent excessive
remodelling, but this will require further study.
The regulation of STC-1 secretion in the
placenta during placental development
The placenta is a highly specialised, pregnancy specific organ that
develops rapidly throughout gestation. The expression of placental
genes varies significantly during pregnancy, with genes regulating the
cell cycle, differentiation, motility and angiogenesis being up-regulated
in early pregnancy, whereas genes involved in lipid metabolism, stress
response and signal transduction are highly expressed at term (Winn
et al., 2007). Transcriptome profiling of human placental gene expres-
sion dynamics from early to mid-gestation has revealed significant ex-
pression of STC-1 during this period with a peak of expression during
mid-gestation. Interestingly, placental STC-1 expression also remains
high at term, but only in complicated pregnancies (Uusküla et al.,
2012). Several single-nucleotide polymorphisms (SNPs) in the STC-1
gene have been identified which appear to directly modulate placental
STC-1 transcript levels (Juhanson et al., 2016). It is possible that these
SNPs explain the observed variation in placental STC-1 gene expres-
sion levels between normal and complicated pregnancies, but this
requires further study (Juhanson et al., 2016). Although the precise
role of placental STC-1 in pregnancy has yet to be elucidated, current
findings in the field suggest that it plays a role in maintaining a healthy
pregnancy, but may also be implicated in the pathology of pregnancy
complications (Abid et al., 2020).
Until recently, the cellular origin of STC-1 in the developing placenta
had not been determined. Immunohistochemical staining of placental
tissue has now revealed that STC-1 is predominantly expressed in the
syncytiotrophoblast and cytotrophoblast cells of the first trimester pla-
centa. STC-1 protein expression is also reported in placental endothe-
lial and stromal cells but at lower expression levels (Abid et al., 2020).
It was also reported that placental cells secrete STC-1 (Abid et al.,
2020) and we are now beginning to understand the mechanisms un-
derlying the regulation of this secretion.
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..Low oxygen conditions (1% O2), combined with induction of intra-
cellular cAMP, have been shown to increase STC-1 secretion from a
choriocarcinoma-derived cytotrophoblast cell line (BeWo) (Abid et al.,
2020). In this cell line, elevated intracellular cAMP induces cell fusion
and differentiation (Wice et al., 1990). In vivo, differentiation of tropho-
blast cells is induced through the same mechanism where cAMP is
stimulated by hCG (Weedon-Fekjær and Taskén, 2012).
Pharmacological modulation of PKA has revealed that the secretion of
STC-1 from BeWo cells is mediated through this pathway (Abid et al.,
2020). Interestingly, elevation of intracellular cAMP alone had no effect
on the secretion of STC-1 by BeWo cells, it was only in combination
with low oxygen that a significant effect on secretion was observed.
Similar data from first trimester chorionic villus tissue shows that STC-
1 secretion was greater under conditions of low oxygen (Abid et al.,
2020). Further investigation of the pathways underlying STC-1 secre-
tion under these conditions has shown that this process is mediated
through activation of the PI3-Kinase/Akt/SGK-1 pathway, primarily
through activation of mTORC-2. In addition, inhibition of the transcrip-
tion factor hypoxia-inducible factor 2a resulted in complete inhibition
of STC-1 secretion in this system, suggesting a key role for this factor
(Abid et al., 2020) (Fig. 2).
The observation of increased STC-1 secretion exclusively under low
oxygen conditions is significant in relation to the in vivo situation. In
early gestation, the oxygen concentration at the maternal–foetal inter-
face is thought be around 1–2% (Rodesch et al., 1992). Around the
10th week of pregnancy, however, blood flow to the developing pla-
centa changes significantly due remodelling of the maternal spiral arter-
ies and the loss of trophoblast plugs (Burton et al., 2009). In
pregnancies that later develop complications such as pre-eclampsia or
fetal growth restriction, this remodelling is insufficient, resulting in pla-
cental under-perfusion and hypoxia (Redman and Sargent, 2001). It is
notable that placental STC-1 expression and secretion are increased in
Figure 2. A schematic overview of the pathway underlying STC-1 secretion from the choriocarcinoma-derived cytotrophoblast
cell line, BeWo, under conditions of low oxygen. AC, adenylyl cyclase; cAMP, cyclic adenosine monophosphate; HIF-2a, hypoxia-inducible
factor-2 alpha; mTORC2, mammalian target of rapamycin complex 2; PKA, protein kinase A; STC-1, stanniocalcin-1.
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pregnancies with these complications (Uusküla et al., 2012; Abid et al.,
2020), therefore it is plausible that low oxygen may be a stimulus for
STC-1 expression in the developing placenta. Correspondingly, in-
creased STC-1 expression in response to low oxygen has also been
observed in several pathological conditions including cerebral ischaemia
(Zhang et al., 2000), carcinogenesis (Chang et al., 2003; Liu et al.,
2010; Ma et al., 2015) and heart failure (Sheikh-Hamad et al., 2003).
In healthy, non-pregnant individuals, STC-1 is absent or undetectable
in the circulation. During pregnancy, however, detectable levels of
STC-1 have been reported, and are suggestive of an endocrine role in
pregnancy (Deol et al., 2000). The source of circulating STC-1 in preg-
nancy is an area of uncertainty in the field. It is postulated that circulat-
ing STC-1 may originate from the ovary, due to the coincident rise in
ovarian STC-1 gene expression with increased serum STC-1 levels
(Deol et al., 2000). It is also thought, however, that the placenta may
be the source of circulating STC-1 due to observed STC-1 secretion
from placental cells (Abid et al., 2020). It is notable that STC-1
remains in the circulation post-partum after the placenta is delivered,
therefore, it is conceivable that circulating STC-1 could originate from
both the placenta and the ovaries, or that the tissue origin changes
post-partum, perhaps to support the physiology of lactation. In preg-
nancies complicated by conditions whose aetiology is thought to occur
in the first trimester, such as pre-eclampsia, fetal growth restriction
and gestational diabetes, third trimester and post-partum serum levels
of STC-1 are even further elevated (Uusküla et al., 2012; Abid et al.,
2020). This is consistent with increased secretion of STC-1 seen in first
trimester placentas derived from pregnancies at risk of developing pre-
eclampsia (Abid et al., 2020). To fully understand the origin and pat-
tern of STC-1 release into the circulation during pregnancy and preg-
nancy complications, however, more comprehensive analysis of
maternal serum is required. As the ovarian STC-1 is structurally dis-
tinct (Paciga et al., 2002), it is plausible that mass spectrometric analy-
sis of serum could identify the tissue-origin of circulating STC-1.
Furthermore, the presence of STC-1 in the circulation in women dur-
ing pregnancy has only been investigated in the third trimester and
post-partum (Uusküla et al., 2012; Juhanson et al., 2016; Abid et al.,
2020), therefore it is unclear at which stage of pregnancy STC-1 is re-
leased into the bloodstream. To understand the pattern of STC-1 re-
lease into the circulation in human pregnancy, longitudinal studies on
maternal serum are required.
Conclusions and future
perspectives
STC-1 was first implicated in the field of female reproduction over
20 years ago, but despite this, we are only now beginning to under-
stand the mechanisms underlying its regulation in female reproductive
tissues and its specific functions in this system. The current data sug-
gest dynamic regulation of STC-1 within ovarian cells and indicate a
paracrine system in which STC-1 is sequestered to target cells for ac-
tion (Deol et al., 2000; Luo et al., 2004; Basini et al., 2010). STC-1
appears to function in the process of ovarian follicular development as
well as in modulating ovarian steroidogenesis (Paciga et al., 2003; Luo
et al., 2004; Baioni et al., 2011; Jepsen et al., 2016). In the human en-
dometrium, the specific function of STC-1 has yet to be elucidated,
however, clear dysregulation of STC-1 in endometrial pathologies indi-
cates a further requirement for study in this area (Aghajanova et al.,
2016; Khatun et al., 2020). Furthermore, uterine expression of STC-1
in early gestation may highlight a key role for this protein in the physi-
ology and pathophysiology of pregnancy. Coincident expression of
STC-1 during blastocyst implantation in most mammalian species, in-
cluding humans, suggests its involvement in the establishment of preg-
nancy (Stasko et al., 2001; Song et al., 2006, 2009; Xiao et al., 2006;
Allegra et al., 2009; Kikuchi et al., 2011). Moreover, expression of
STC-1 in the developing placenta and altered expression in compli-
cated pregnancies highlights the requirement of STC-1 for maintenance
of a healthy pregnancy but suggests that its expression must be tightly
regulated (Uusküla et al., 2012; Juhanson et al., 2016; Abid et al.,
2020). It is evident that expression of STC-1 in most cells types is me-
diated through the PKA pathway and is induced by cAMP (Paciga
et al., 2002, 2004; Aghajanova et al., 2016; Abid et al., 2020; Khatun
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verse biological processes, are strongly suggestive of a pivotal role in
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